Human recombinant leptin ("metreleptin")
PreclinicalSmall molecule
Human recombinant leptin ("metreleptin") is one of 10 small molecule programs targeting Lipodystrophy. It is currently in Preclinical.
1
Indications
1
Total Trials
0
Active Trials
9
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
9 competitors in Lipodystrophy
#DrugCompanyPhaseTrials
1Actos
TakedaApproved
Ziagen
GSKApproved
Sustiva
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Zerit
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Viracept
AAgouron Pharmaceuticals
Approved
Epivir
GGlaxo Dba Glaxosmithkline
Approved
Myalept
Chiesi Farmaceutici S.p.A.Phase 3
Isentress
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Preclinical
Recombinant Human Growth Hormone
Changchun GeneScience Pharmaceutical Co., Ltd.Preclinical
Human recombinant leptin ("metreleptin")
BBaylor College of Medicine
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Lipodystrophy1 trial
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
Completed·—·N/A·NCT01511016·17 enrolled
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- BBaylor College of Medicine